Current PTSD treatment guidelines recommend against cannabinoids for PTSD, according to a 2026 scoping review in the Journal of Cannabis Research. The studies that report benefit are mostly observational or low quality. In that review, only one of seven randomized trials showed a clear benefit over placebo, and it was for PTSD-related nightmares. If you live with PTSD, the step that matters most is a qualified mental health assessment followed by a treatment plan.
What does the VA guideline recommend?
The 2026 review says current treatment guidelines recommend against cannabinoids for PTSD. Its abstract does not name which guidelines it means, and the studies here do not quote the VA’s wording. Read the VA’s current PTSD guideline directly and check its publication date before you rely on any wording, including the wording in this summary.
How does a recommendation differ from a personal testimonial?
A guideline recommendation is a clinical position that weighs the full body of studies, including how well each one was designed. A testimonial is one person’s account of what happened to them. It can show why people try cannabis, but it cannot show whether cannabis caused the change. Research on PTSD has the same problem at a larger scale:
- The 2015 review in Primary Care Companion for CNS Disorders concluded that most reports were correlational and observational, and that the direction of effect between cannabis use and PTSD could not be established.
- The 2026 review found that observational studies frequently reported symptom improvements, especially in nightmares, hyperarousal, sleep and quality of life. It rated those findings as limited by high risk of bias, self-reported outcomes and lack of control groups.
- The 2015 review also describes a 75% reduction in CAPS scores reported by Greer and colleagues in patients evaluated for New Mexico’s medical cannabis program. That is an observational report, not a randomized comparison.
State medical marijuana programs are a separate matter. The 2015 review notes that in at least 8 states, PTSD was one of the approved indications for medical marijuana, and that this approval happened under state authority, without FDA approval.
What do the controlled studies show?
The table below sets out the population, cannabis formulation, comparator, outcome, duration and harms for each review and study. Where an abstract does not state a duration, the table says so.
| Study | Population | Formulation | Comparator | Outcome | Duration | Harms | Certainty |
|---|---|---|---|---|---|---|---|
| 2026 scoping review (26 studies, 3,598 patients) | People with PTSD | Nabilone; inhaled or oral cannabis; oral THC; acute oral CBD | Placebo in the seven RCTs | PTSD symptom severity, including nightmares | Not stated in abstract | Mostly mild, such as dry mouth and dizziness | Insufficient from high-quality RCTs; one of seven RCTs showed clear benefit |
| 2021 AIMS review (1 RCT, 10 observational studies, n = 4,672) | People with PTSD | Cannabis (product type not specified in abstract) | Mostly none; non-randomized studies without comparators | PTSD symptoms, quality of life, return to work | Not stated in abstract | Dry mouth, headaches, agitation, euphoria; a small proportion worsened | Low quality; high risk of bias |
| 2019 Medicina systematic review | People with PTSD | Medicinal cannabis and synthetic cannabinoids | Not stated in abstract | Anxiety, memory-related processes and sleep, described as potential benefits | Not stated in abstract | Safety data described as limited | Limited evidence on safety and efficacy |
| 2015 review (46 articles) | People with PTSD; medical marijuana users | Medical marijuana (type not specified) | Mostly none; observational and correlational designs | Symptom reports | Not stated | Link with problematic cannabis use noted | Lack of large randomized trials; direction of effect unclear |
| 2021 VA study (340 veterans) | Veterans receiving outpatient PTSD care | Cannabis use during treatment; quantity and composition not determinable | Veterans with no cannabis use (259) | Treatment success (5-point or greater PCL drop): 51.9% vs 51.4% | Number of sessions between baseline and follow-up PTSD Checklist scores | Not reported in this study | Retrospective chart review; no significant association after adjustment |
| 2023 Australian clinician review | Clinicians treating PTSD | Medicinal cannabis, alongside trauma-focused therapy | Not applicable | Practical and safety challenges, not an outcome measure | Not stated in abstract | Addiction potential; dose timing and titration concerns | Expert opinion, not an efficacy study |
The 2021 VA study followed 340 veterans receiving outpatient PTSD care. Treatment success, defined as a drop of at least five points on the PTSD Checklist, occurred in 51.9% of veterans who used cannabis and 51.4% of those who did not. After adjustment, cannabis use did not significantly change the odds of success. The authors note the study was retrospective, mostly included white men, and could not determine the quantity or composition of the cannabis used. For a wider view of how cannabinoid research compares across conditions, see the Cannabis Evidence Comparison Chart.
Federal study finds cannabis beneficial for PTSD treatment: what do the studies show?
The studies on this page do not support a claim that cannabis is beneficial for PTSD treatment overall. The 2026 scoping review found that only one of seven RCTs, a nabilone versus placebo trial, showed a statistically significant reduction in PTSD-related nightmares. The 2015 review notes that two large government-sponsored studies concluded there were too few studies to determine the usefulness of medical marijuana, while both called for more research. For the CBD side of this question, see the CBD and PTSD research review.
What is cannabis use disorder (CUD), and is it a risk with PTSD?
The 2015 review notes a higher chance of cannabis use disorder among adults with PTSD, while stating that the direction of cause is not established. The sources here do not include diagnostic criteria or a prevalence figure for cannabis use disorder, so a qualified clinician is the right person to assess it.
Among veterans, the 2021 VA study cites a 2017 study finding that Iraq/Afghanistan-era veterans with cannabis use disorder had 1.7 times higher current suicidal ideation and 2.3 times higher lifetime suicide attempts than veterans without it. If cannabis is part of your picture, say so at your assessment.
What are the symptoms of cannabis-induced anxiety disorder?
The sources here do not define a diagnosis called cannabis-induced anxiety disorder, and they do not list its symptoms. The 2015 review reports associations between anxiety or depression and problematic cannabis use patterns, and states that the direction of cause is not established. Tell your clinician what you use and when, so they can sort out what is driving the symptoms.
What counts as chronic or heavy use, and do the benefits of quitting last?
The sources here do not define chronic or heavy cannabis use. No source here sets a number of joints per day that counts as heavy use, and the VA study notes that quantity was often not documented, so no threshold can be read from this research. The 2015 review notes that discontinuation may be followed by withdrawal, greater PTSD symptoms and craving, as described by Boden and colleagues. None of the studies here measure the long-term benefits of quitting in people with PTSD, and the sources here do not cover cannabinoid hyperemesis syndrome or treatment options for cannabis use disorder. Ask your clinician what changes to expect and which options fit your situation.
Are edibles, indica or sativa, or a best product better for PTSD?
None of the studies here compare indica and sativa. The VA study noted that the cannabinoid content of the cannabis used could not be determined from chart records. The studies also do not compare edibles with other forms for PTSD, and the sources here do not address how quickly edibles take effect or their harms. No source here supports naming any product as best for PTSD, and this page does not recommend products.
What the research cannot tell you
- Whether cannabis helps PTSD over the long term. The controlled studies are small, and most abstracts do not state how long treatment lasted.
- Which cannabinoid, dose or product might help, if any. The studies used different substances and forms, which makes them hard to compare.
- How cannabis relates to complex PTSD. None of the sources here address it.
- Whether cannabis causes PTSD symptoms or PTSD drives cannabis use. The reviews say this is not established.
Your next step: a qualified mental health assessment
For general background on cannabis health effects, CDC’s Cannabis Health Effects page and NIDA’s Cannabis (Marijuana) research topic page are good places to start.
If PTSD symptoms are part of your life, the next step is an assessment with a qualified mental health clinician, followed by a treatment plan built with them. Bring a complete list of what you use, including cannabis, how often you use it, and what you have noticed about your mood, sleep and nightmares. Ask what the research means for your situation and which options fit it. Ask your clinician before changing any prescribed medicine.
By TakeHempGummies.com Consumer Research Desk
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.